GlassScriptPhysician profile
Cristin Ann Weicker
NPI 1114910320
$4,392.44
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,485 · 2020: $1,195 · 2021: $943 · 2022: $451 · 2023: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $318.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,042.54 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $459.64 | 2019-2021 | |
| Pfizer INC. | $399.80 | 2019-2023 | |
| Lilly USA, LLC | $319.89 | 2019-2022 | |
| Amgen INC. | $310.87 | 2019-2023 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.61 | 2019-2022 | |
| Abbvie INC. | $258.85 | 2020-2023 | Qulipta |
| Janssen Pharmaceuticals, INC | $240.37 | 2019-2021 | |
| Glaxosmithkline, LLC. | $173.70 | 2019-2022 | |
| Astellas Pharma US INC | $138.71 | 2019-2021 | |
| Amarin Pharma, INC. | $105.38 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $91.70 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $86.72 | 2019-2021 | |
| Mylan Specialty L.P. | $70.69 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $62.03 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $59.60 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $47.48 | 2019-2020 | |
| Ibsa Pharma INC. | $47.30 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.60 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $27.82 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $24.80 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $20.99 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.63 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.22 | 2020 | |
| Esperion Therapeutics, INC. | $12.94 | 2021 | |
| Sanofi Pasteur INC. | $12.26 | 2019 | |
| Allergan, INC. | $12.17 | 2020 | |
| Philips North America LLC | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristin Weicker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.